Eli Lilly Slashes Zepbound Prices by up to 50%
Eli Lilly announces discount Zepbound prices slash for 2.5 and 5.5 mg vials.
We’ve extensively discussed Mounjaro and Zepbound weight loss treatments and the significant benefits of using Tirzepatide for obesity. While millions benefit from these treatments, the primary concern has always been the price.
Zepbound Prices Slashed for Major Savings
Since Tirzepatide’s market debut, Zepbound and Mounjaro have faced persistent shortages, primarily due to issues with pens and injectors. In response to these shortages and the growing demand for more affordable options, Eli Lilly has introduced a substantial price cut for Zepbound, which customers will appreciate.
Eli Lilly & Co. recently announced that patients can now obtain 2.5 mg and 5 mg single-dose vials of Zepbound, a weight-loss treatment, at a discounted price—at least 50% less than other incretin medicines for obesity—when prescribed on-label.
Lilly Introduces Discount Zepbound Pricing
No Zepbound coupon is required! If you’re looking to use the name-brand Tirzepatide for weight loss, there’s good news. While you might experience some sticker shock with the new discount Zepbound prices, I will say – it is now more than 50% off the original retail pricing.
A four-week supply of the 2.5 mg Zepbound single-dose vial is now available for $399 ($99.75 per vial), and a four-week supply of the 5 mg dose is $549 ($137.25 per vial). This pricing is less than half the cost of other incretin medicines for obesity and aligns with the Zepbound savings program for those without coverage.
The self-pay channel provides a transparent price by eliminating third-party supply chain entities, allowing patients to access these savings directly, outside of insurance.
This price reduction is a significant advantage for those using compound pharmacies for Tirzepatide but preferring the name-brand product.
Zepbound Vial Not Pen
The discount Zepbound prices does have one change anyone using name brand weight loss Tirezepatide will need to be aware of. Eli Lilly is offering Zepbound vials not the typical injector pen that many are use to.
We talk about the Zepbound vials to learn what to expect if you are making the switch from pen to vial.
“These new vials not only help us meet the high demand for our obesity medicine but also expand access for patients seeking a safe and effective treatment option. In a clinical study, the 5 mg maintenance dose helped patients achieve an average of 15% weight loss after 72 weeks of treatment and has been a powerful tool for millions of people with obesity looking to lose weight and keep it off,” says in a Eli Lilly press release quoting Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA.
By distributing the vials via LillyDirect, patients can be assured they are receiving genuine Lilly products. The weight-loss industry has been flooded with counterfeits and knockoffs that can pose serious health risks.
The Zepbound pens were also a reason for many of the shortages. Many of us know the Mounjaro shortages that have been consistent since the product released over 2 years ago.
Understanding Zepbound and Insurance Options
Zepbound is Tirzepatide formulated for weight loss, whereas Mounjaro is Tirzepatide intended for diabetes management.
This new pricing strategy for Zepbound also benefits those who have struggled to get insurance approval for Tirzepatide. Through Lilly Direct, patients can connect with a doctor for a prescription and order discounted Zepbound.
While the prices of $399 and $549 may still be steep, they represent a significant discount, making Zepbound more accessible to those unable to obtain insurance approval.
The reduced Zepbound price marks a major victory. With big pharma under scrutiny for high prices, this move by Lilly is a critical step forward in the fight against obesity.
Want to learn more? We share a Mounjaro weight loss journey to help you get a personal story of conquering obesity with Tirezepatide.